PET in the management of locally advanced and metastatic NSCLC
- 28 April 2015
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 12 (7) , 395-407
Abstract
Despite considerable improvements in the treatment options for advanced-stage non-small-cell lung cancer (NSCLC), disease-specific survival remains poor. With the aim of improving patient outcome, the treatment paradigm of locally advanced NSCLC has shifted from solely radiotherapy towards combined and intensified treatment approaches. Also, treatment for patients with stage IV (oligo)metastatic NSCLC has evolved rapidly, with therapeutic options that include a number of targeted agents, surgery, and stereotactic ablative radiotherapy. However, personalizing treatment to the individual patient remains difficult and requires monitoring of biological parameters responsible for treatment resistance to facilitate treatment selection, guidance, and adaptation. PET is a well-established molecular imaging platform that enables non-invasive quantification of many biological parameters that are relevant to both local and systemic therapy. With increasing clinical evidence, PET has gradually evolved from a purely diagnostic tool to a multifunctional imaging modality that can be utilized for treatment selection, adaptation, early response monitoring, and follow up in patients with NSCLC. Herein, we provide a comprehensive overview of the available clinical data on the use of this modality in this setting, and discuss future perspectives of PET imaging for the clinical management of patients with locally advanced and metastatic NSCLC.Keywords
This publication has 121 references indexed in Scilit:
- The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancerRadiotherapy and Oncology, 2012
- PET scans in radiotherapy planning of lung cancerLung Cancer, 2012
- Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validationLung Cancer, 2012
- [18F]fluorodeoxyglucose Uptake Patterns in Lung Before Radiotherapy Identify Areas More Susceptible to Radiation-Induced Lung Toxicity in Non-Small-Cell Lung Cancer PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Partial volume correction strategies for quantitative FDG PET in oncologyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Adaptive Radiotherapy for Lung CancerSeminars in Radiation Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)Lung Cancer, 2008
- Prospective assessment of dosimetric/physiologic-based models for predicting radiation pneumonitisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006